BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics

The blockbuster immunomodulatory drug Revlimid (lenalidomide), which has become a backbone of many multiple myeloma treatment regimens and Bristol Myers Squibb Company’s top-selling drug, will face its first generics this year. Combined, generics for Revlimid and the chemotherapy drug Abraxane (nab-paclitaxel) will take about a $3bn bite out of the company’s 2022 revenue, according to new guidance from Bristol on 10 January, but current and future blockbusters are expected to fill that gap.

CEO Giovanni Caforio, in his same-day presentation at the J.P. Morgan Healthcare Conference, reiterated the company’s expectation that it will see more than $25bn in sales from new products by...